Rhino Health Joins The FNIH Biomarkers Consortium

The Foundation for the National Institutes of Health (FNIH) supports translation through public-private partnerships

By bringing together the reach and scale of public institutions with the expertise and rapid innovation cycles of leading enterprises, public-private partnerships have tremendous potential to improve healthcare for many people. But facilitating, monitoring, and leading this type of groundbreaking work requires care, experience, resources, and hard work.

The Foundation for the National Institutes of Health (FNIH) was established by the US Congress in 1990 as a not-for-profit, 501(c)(3) charitable organization. FNIH creates and leads alliances between public and private institutions in support of the mission of the NIH and White House. It organizes and administers research programs, organizes educational events, and administers funds that support a wide range of health challenges. To date, the FNIH has raised $1.2 billion USD (90% directly supporting products) and currently enlists 100+ active programs.

The Biomarkers Consortium was founded in 2006, as a specific biomedical research program within the FNIH. Specifically, it works to identify, develop, and qualify potential biomarkers to improve drug development and regulatory decision-making. To date, over $100 million USD has been raised and over 35 projects initiated, leading to over 50 publications and many accomplishments in therapeutics and clinical tools, such as label expansion for medications addressing debilitating diseases and learnings that have changed FDA regulatory programs. The Biomarkers Consortium has four major Steering Committees: Cancer, Metabolic Disorders, Neuroscience, and Inflammation & Immunity. Private sector members include major pharmaceutical, health tech, and large biotech companies.

Rhino Health is excited to announce it is joining the Biomarkers Consortium and will be represented on all four steering committees. As members, Rhino Health will shape active and new projects, bringing our cross-functional, proprietary experience in distributed compute, AI development, and the life sciences industry to the table. Rhino Health will offer the use of the Rhino Health Platform, enabling researchers with privacy-preserving data management and computation to enhance and de-risk public-private partnerships, working side-by-side with world leaders in healthcare to push the envelope further. Ultimately, the aim is to advance the core mission that is mutual between the FNIH and Rhino Health: to improve the lives of patients.

‍